News from pharmaceutical companies and other related healthcare organizations
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine
Recordati Rare Diseases, Inc., based in Lebanon, NJ, has recently acquired the rights to SIGNIFOR® LAR and the FDA approval for ISTURISA®(osilodrostat). Both products treat pituitary diseases. SIGNIFOR LAR, a “2nd generation” somatostatin analog given
If you are currently taking, or are about to start taking Lanreotide (Somatuline Depot) injections, this website from Ipsen offers a wealth of information about patient access to therapies. IPSEN CARES serves as a central